Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ: BDTX · Real-Time Price · USD
2.700
-0.220 (-7.53%)
At close: Apr 28, 2026, 4:00 PM EDT
2.720
+0.020 (0.74%)
After-hours: Apr 28, 2026, 7:00 PM EDT
BDTX Revenue
In the year 2025, Black Diamond Therapeutics had annual revenue of $70.00M.
Revenue (ttm)
$70.00M
Revenue Growth
n/a
P/S Ratio
2.23
Revenue / Employee
$3,333,333
Employees
21
Market Cap
154.68M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 114.20M |
| Spero Therapeutics | 66.80M |
| ProQR Therapeutics | 19.19M |
| Fate Therapeutics | 6.65M |
| Alps Group | 3.74M |
| Oramed Pharmaceuticals | 2.00M |
| Molecular Partners AG | 856.30K |
| Spruce Biosciences | 697.00K |
BDTX News
- 7 days ago - Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting - GlobeNewsWire
- 6 weeks ago - Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Black Diamond Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 months ago - Black Diamond Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference - Transcripts
- 5 months ago - Black Diamond's Lung Cancer Drug Shows 60% Response Rate In Phase 2 Data - Benzinga
- 5 months ago - Black Diamond Therapeutics Transcript: Study Update - Transcripts
- 5 months ago - Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM - GlobeNewsWire